Rock Creek Pharmaceuticals Inc. (RCPI) 0.27 $RCPI
Rock Creek Pharmaceuticals to Webcast Presentation at the Biotech Showcase 2015 in San Francisco on Monday, January 12, at 4:00PM Pacific
PR Newswire Europe - Mon Jan 05, 7:38AM CST
Rock Creek Pharmaceuticals, Inc., [http://www.rockcreekpharmaceuticals.com/] , a drug development company focused on chronic inflammatory disease and neurologic disorders, announced that the Company's presentation at the Biotech Showcase(TM) 2015, taking place in San Francisco, CA, is scheduled for Monday, January 12th at 4:00PM PT (7:00 PM ET) in the "Mission I" room of the Parc 55 Wyndham in Union Square.
RCPI: 0.27 (+0.01)
Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations
PR Newswire - Tue Dec 23, 9:00AM CST
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced today that it has filed a Clinical Trial Application (CTA) with the United Kingdom's Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to initiate clinical trials for the continued development of its lead molecule, Anatabine Citrate.
RCPI: 0.27 (+0.01)
Rock Creek Pharmaceuticals Announces Listing Extension on NASDAQ
PR Newswire - Thu Dec 11, 3:32PM CST
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that it received notification from the Nasdaq Stock Market, Inc. granting a six-month extension of its Nasdaq listing. The Company has until April 27, 2015 to maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive days to maintain compliance with Nasdaq listing requirements. The extension is also subject to the condition that the Company provide certain written updates to Nasdaq during the extension period and that Rock Creek file, on or before February 23, 2015, a preliminary proxy statement for a shareholder meeting for a reverse stock split proposal.
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
Pre-Market Scans on Personal Products Stocks -- Estee Lauder Cos., Coty, Herbalife, Nu Skin Enterprises, and Rock Creek Pharma
PR Newswire - Tue Dec 09, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: The Estee Lauder Companies Inc. (NYSE: EL), Coty Inc. (NYSE: COTY), Herbalife Ltd (NYSE: HLF), Nu Skin Enterprises Inc. (NYSE: NUS), and Rock Creek Pharmaceuticals Inc. (NASDAQ: RCPI). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, December 08, 2014, ended on a negative note as the Dow Jones Industrial Average finished at 17,852.48, down 0.59% and the NASDAQ Composite closed at 4,740.69, down 0.84%. The S&P 500 finished the session 0.73% lower at 2,060.31. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Consumer Staples Sector Index ended the day at 500.29, down 0.23%, whereas the index has advanced 7.67% in the previous three months. Register for your complimentary reports on these five stocks at:
HLF: 32.73 (-0.59), COTY: 19.32 (-0.54), RCPI: 0.27 (+0.01), NUS: 40.84 (-0.77), EL: 74.26 (-0.64)
Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015
PR Newswire - Fri Nov 21, 7:30AM CST
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
Rock Creek Pharmaceuticals EPS of -$0.03
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:25PM CST
RCPI: 0.27 (+0.01)
Rock Creek Pharmaceuticals Reports Third Quarter 2014 Results and Provides Business Update
PR Newswire - Mon Nov 10, 4:00PM CST
Rock Creek Pharmaceuticals, Inc., (RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today its financial results for the third quarter ended September 30, 2014 and provided a business update. The Company's Form 10-Q was filed with the Securities Exchange Commission.
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
5 Breakout Stocks Under $10 Set to Soar
at The Street - Fri Oct 31, 1:12PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
CXDC: 4.93 (+0.04), CTG: 8.42 (-0.07), RCPI: 0.27 (+0.01), NADL: 1.25 (-0.16), BBLU: 1.32 (-0.05)
4 Stocks Under $10 Making Big Moves Higher
at The Street - Fri Oct 31, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
ELOS: 10.92 (+0.05), RCPI: 0.27 (+0.01), CRCM: 7.39 (-0.26), RST: 8.89 (-0.09)
Rock Creek Pharmaceuticals Announces Presentation of Four Anatabine Projects at Neuroscience 2014
PR Newswire - Thu Oct 23, 8:06AM CDT
Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that abstracts outlining four separate preclinical studies evaluating anatabine, the primary constituent in the Company's lead investigational compound anatabine citrate, have been accepted for poster and nano symposium presentations at the upcoming annual meeting of the Society for Neuroscience, taking place November 15-19 in Washington, DC. This meeting is the premier event in the field, typically attracting approximately 30,000 attendees, with 15,000 scientific presentations and nearly 600 presenting companies.
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Oct 15, 6:00AM CDT
Keep these under-$10 biotech stocks on your breakout trading radar.
ATNM: 5.17 (-0.29), RCPI: 0.27 (+0.01), RGDO: 0.90 (-0.02)
Microchip Technology Dips On Sales Warning
at The Street - Fri Oct 10, 12:04PM CDT
Billionaire stock picks EXACT Sciences Corporation (NASDAQ:EXAS), Nanosphere, Inc. (NASDAQ:NSPH) and Rock Creek Pharmaceuticals Inc (NASDAQ:RCPI) are making noteworthy gains on the market this Friday...
RCPI: 0.27 (+0.01), MCHP: 44.03 (-0.49), KN: 24.01 (-0.66), EXAS: 27.19 (-1.97), NSPH: 0.35 (-0.02)
Bankruptcy Filing Fallout Continues For NII Holdings
at The Street - Fri Sep 19, 4:16PM CDT
Corinthian Colleges Inc (NASDAQ:COCO), Rock Creek Pharmaceuticals Inc (NASDAQ:RCPI) and dELiA*s, Inc. (NASDAQ
LIA) are today's top-gaining stocks. The losers are NII Holdings Inc (NASDAQ:NIHD), T...
ENZN: 1.01 (-0.01), DLIA: 0.01 (unch), RCPI: 0.27 (+0.01), COCO: 0.06 (-0.01), TAS: 0.40 (-0.02), NIHD: 0.06 (-0.01)
Rite Aid Plunges As Full-Year Outlook Dims
at The Street - Thu Sep 18, 12:04PM CDT
KiOR Inc (NASDAQ:KIOR), NII Holdings Inc (NASDAQ:NIHD) and Rock Creek Pharmaceuticals Inc (NASDAQ:RCPI) are this Thursday's top-gaining billionaire investment picks. On the losing end are Repros ...
RCPI: 0.27 (+0.01), RPRX: 9.04 (-0.31), NIHD: 0.06 (-0.01), RAD: 7.79 (-0.04)
Rock Creek Pharmaceuticals Receives New Dietary Ingredient Notification (NDIN) Response
PR Newswire - Fri Sep 12, 7:30AM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today it has received a written response from the U.S. Food and Drug Administration (FDA) in response to the New Dietary Ingredient Notification (NDIN) for the formulations of Anatabloc® and CigRx® submitted by the Company in June 2014. The letter indicated that the FDA considers anatabine citrate, a principal ingredient in these products, to be a drug, because anatabine citrate is intended to provide anti-inflammatory support, and is the subject of a previously filed Investigational New Drug Application (INDA).
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
Firm halting sales of dietary supplement Anatabloc
By MICHAEL FELBERBAUM - AP - Mon Aug 11, 5:45PM CDT
RICHMOND, Va. (AP) — The dietary supplement maker at the center of a federal trial of former Virginia Gov. Bob McDonnell and his wife is halting sales of its product called Anatabloc.
RCPI: 0.27 (+0.01)
Rock Creek Pharmaceuticals Reports Second Quarter and Announces Clinical Update
PR Newswire - Mon Aug 11, 3:20PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that it filed with the Securities Exchange Commission its Form 10-Q for the second quarter ended June 30, 2014. The company has also announced a clinical and regulatory update.
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
Rock Creek Pharmaceuticals Expands The Board with the Appointment of Two Independent Directors
PR Newswire - Wed Aug 06, 12:04PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has made two key independent appointments to the Company's Board of Directors with the recent election of Ms. Lee M. Canaan, CFA and Mr. Edward J. McDonnell, MPH. as new directors.
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference
PR Newswire - Mon Aug 04, 1:49PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has been selected to present at the Next Generation Track at BioPharm America 2014 in Boston (Sept. 22-24, 2014) at The Boston Marriott Copley Place.
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
Rock Creek Pharmaceuticals to Webcast Presentation at the Biotech Showcase 2015 in San Francisco on Monday, January 12, at 4:00PM Pacific
PR Newswire Europe - Mon Jan 05, 7:38AM CST
Rock Creek Pharmaceuticals, Inc., [http://www.rockcreekpharmaceuticals.com/] , a drug development company focused on chronic inflammatory disease and neurologic disorders, announced that the Company's presentation at the Biotech Showcase(TM) 2015, taking place in San Francisco, CA, is scheduled for Monday, January 12th at 4:00PM PT (7:00 PM ET) in the "Mission I" room of the Parc 55 Wyndham in Union Square.
RCPI: 0.27 (+0.01)
Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations
PR Newswire - Tue Dec 23, 9:00AM CST
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced today that it has filed a Clinical Trial Application (CTA) with the United Kingdom's Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to initiate clinical trials for the continued development of its lead molecule, Anatabine Citrate.
RCPI: 0.27 (+0.01)
Rock Creek Pharmaceuticals Announces Listing Extension on NASDAQ
PR Newswire - Thu Dec 11, 3:32PM CST
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that it received notification from the Nasdaq Stock Market, Inc. granting a six-month extension of its Nasdaq listing. The Company has until April 27, 2015 to maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive days to maintain compliance with Nasdaq listing requirements. The extension is also subject to the condition that the Company provide certain written updates to Nasdaq during the extension period and that Rock Creek file, on or before February 23, 2015, a preliminary proxy statement for a shareholder meeting for a reverse stock split proposal.
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
Pre-Market Scans on Personal Products Stocks -- Estee Lauder Cos., Coty, Herbalife, Nu Skin Enterprises, and Rock Creek Pharma
PR Newswire - Tue Dec 09, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: The Estee Lauder Companies Inc. (NYSE: EL), Coty Inc. (NYSE: COTY), Herbalife Ltd (NYSE: HLF), Nu Skin Enterprises Inc. (NYSE: NUS), and Rock Creek Pharmaceuticals Inc. (NASDAQ: RCPI). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, December 08, 2014, ended on a negative note as the Dow Jones Industrial Average finished at 17,852.48, down 0.59% and the NASDAQ Composite closed at 4,740.69, down 0.84%. The S&P 500 finished the session 0.73% lower at 2,060.31. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Consumer Staples Sector Index ended the day at 500.29, down 0.23%, whereas the index has advanced 7.67% in the previous three months. Register for your complimentary reports on these five stocks at:
HLF: 32.73 (-0.59), COTY: 19.32 (-0.54), RCPI: 0.27 (+0.01), NUS: 40.84 (-0.77), EL: 74.26 (-0.64)
Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015
PR Newswire - Fri Nov 21, 7:30AM CST
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
Rock Creek Pharmaceuticals EPS of -$0.03
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:25PM CST
RCPI: 0.27 (+0.01)
Rock Creek Pharmaceuticals Reports Third Quarter 2014 Results and Provides Business Update
PR Newswire - Mon Nov 10, 4:00PM CST
Rock Creek Pharmaceuticals, Inc., (RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today its financial results for the third quarter ended September 30, 2014 and provided a business update. The Company's Form 10-Q was filed with the Securities Exchange Commission.
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
5 Breakout Stocks Under $10 Set to Soar
at The Street - Fri Oct 31, 1:12PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
CXDC: 4.93 (+0.04), CTG: 8.42 (-0.07), RCPI: 0.27 (+0.01), NADL: 1.25 (-0.16), BBLU: 1.32 (-0.05)
4 Stocks Under $10 Making Big Moves Higher
at The Street - Fri Oct 31, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
ELOS: 10.92 (+0.05), RCPI: 0.27 (+0.01), CRCM: 7.39 (-0.26), RST: 8.89 (-0.09)
Rock Creek Pharmaceuticals Announces Presentation of Four Anatabine Projects at Neuroscience 2014
PR Newswire - Thu Oct 23, 8:06AM CDT
Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that abstracts outlining four separate preclinical studies evaluating anatabine, the primary constituent in the Company's lead investigational compound anatabine citrate, have been accepted for poster and nano symposium presentations at the upcoming annual meeting of the Society for Neuroscience, taking place November 15-19 in Washington, DC. This meeting is the premier event in the field, typically attracting approximately 30,000 attendees, with 15,000 scientific presentations and nearly 600 presenting companies.
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Oct 15, 6:00AM CDT
Keep these under-$10 biotech stocks on your breakout trading radar.
ATNM: 5.17 (-0.29), RCPI: 0.27 (+0.01), RGDO: 0.90 (-0.02)
Microchip Technology Dips On Sales Warning
at The Street - Fri Oct 10, 12:04PM CDT
Billionaire stock picks EXACT Sciences Corporation (NASDAQ:EXAS), Nanosphere, Inc. (NASDAQ:NSPH) and Rock Creek Pharmaceuticals Inc (NASDAQ:RCPI) are making noteworthy gains on the market this Friday...
RCPI: 0.27 (+0.01), MCHP: 44.03 (-0.49), KN: 24.01 (-0.66), EXAS: 27.19 (-1.97), NSPH: 0.35 (-0.02)
Bankruptcy Filing Fallout Continues For NII Holdings
at The Street - Fri Sep 19, 4:16PM CDT
Corinthian Colleges Inc (NASDAQ:COCO), Rock Creek Pharmaceuticals Inc (NASDAQ:RCPI) and dELiA*s, Inc. (NASDAQ
LIA) are today's top-gaining stocks. The losers are NII Holdings Inc (NASDAQ:NIHD), T... ENZN: 1.01 (-0.01), DLIA: 0.01 (unch), RCPI: 0.27 (+0.01), COCO: 0.06 (-0.01), TAS: 0.40 (-0.02), NIHD: 0.06 (-0.01)
Rite Aid Plunges As Full-Year Outlook Dims
at The Street - Thu Sep 18, 12:04PM CDT
KiOR Inc (NASDAQ:KIOR), NII Holdings Inc (NASDAQ:NIHD) and Rock Creek Pharmaceuticals Inc (NASDAQ:RCPI) are this Thursday's top-gaining billionaire investment picks. On the losing end are Repros ...
RCPI: 0.27 (+0.01), RPRX: 9.04 (-0.31), NIHD: 0.06 (-0.01), RAD: 7.79 (-0.04)
Rock Creek Pharmaceuticals Receives New Dietary Ingredient Notification (NDIN) Response
PR Newswire - Fri Sep 12, 7:30AM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today it has received a written response from the U.S. Food and Drug Administration (FDA) in response to the New Dietary Ingredient Notification (NDIN) for the formulations of Anatabloc® and CigRx® submitted by the Company in June 2014. The letter indicated that the FDA considers anatabine citrate, a principal ingredient in these products, to be a drug, because anatabine citrate is intended to provide anti-inflammatory support, and is the subject of a previously filed Investigational New Drug Application (INDA).
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
Firm halting sales of dietary supplement Anatabloc
By MICHAEL FELBERBAUM - AP - Mon Aug 11, 5:45PM CDT
RICHMOND, Va. (AP) — The dietary supplement maker at the center of a federal trial of former Virginia Gov. Bob McDonnell and his wife is halting sales of its product called Anatabloc.
RCPI: 0.27 (+0.01)
Rock Creek Pharmaceuticals Reports Second Quarter and Announces Clinical Update
PR Newswire - Mon Aug 11, 3:20PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that it filed with the Securities Exchange Commission its Form 10-Q for the second quarter ended June 30, 2014. The company has also announced a clinical and regulatory update.
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
Rock Creek Pharmaceuticals Expands The Board with the Appointment of Two Independent Directors
PR Newswire - Wed Aug 06, 12:04PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has made two key independent appointments to the Company's Board of Directors with the recent election of Ms. Lee M. Canaan, CFA and Mr. Edward J. McDonnell, MPH. as new directors.
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference
PR Newswire - Mon Aug 04, 1:49PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has been selected to present at the Next Generation Track at BioPharm America 2014 in Boston (Sept. 22-24, 2014) at The Boston Marriott Copley Place.
STSI: 0.58 (-0.05), RCPI: 0.27 (+0.01)
